Education
About Us
Working with TipRanks
Follow Us
PureTech Health (PRTC)
NASDAQ:PRTC
PRTC Stock Chart & Stats
$17.94
-$0.90(-4.78%)
At close: 4:00 PM EST
$17.94
-$0.90(-4.78%)
Day’s Range― - ―
52-Week Range$13.30 - $24.99
Previous CloseN/A
Volume2.03K
Average Volume (3M)4.23K
Market Cap
$428.83M
Enterprise Value$106.53M
Total Cash (Recent Filing)$321.55M
Total Debt (Recent Filing)$20.92M
Price to Earnings (P/E)9.9
Beta0.55
Next Earnings
Apr 23, 2026EPS Estimate
-1.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding24,168,404
10 Day Avg. Volume1,378
30 Day Avg. Volume4,231
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.20
Price to Sales (P/S)103.10
P/FCF Ratio-3.70
Enterprise Value/Market Cap0.25
Enterprise Value/Revenue18.12
Enterprise Value/Gross Profit5.35
Enterprise Value/Ebitda1.91
Forecast
1Y Price Target
$46.00Price Target Upside156.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe positive Phase 2b ELEVATE data supports moving ahead to Phase 3, showing a greater benefit on FVC compared to pirfenidone with a similar safety profile.
Drug DevelopmentLYT-100, as a deuterated version of an improved anti-fibrotic, may mitigate some of the clinical risks seen with other candidates in the idiopathic pulmonary fibrosis landscape.
Strategic InitiativesPRTC announced the launch of a new private company, Celea Therapeutics, which will comprise the LYT-100 (deupirfenidone) program.
Bears Say
FinancingNo financing was announced in conjunction with the NewCo, though it is expected to be a subsequent step.
PureTech Health News
PRTC FAQ
What was PureTech Health’s price range in the past 12 months?
PureTech Health lowest stock price was $13.30 and its highest was $24.99 in the past 12 months.
What is PureTech Health’s market cap?
PureTech Health’s market cap is $428.83M.
When is PureTech Health’s upcoming earnings report date?
PureTech Health’s upcoming earnings report date is Apr 23, 2026 which is in 187 days.
How were PureTech Health’s earnings last quarter?
PureTech Health released its earnings results on Aug 28, 2025. The company reported -$1.9 earnings per share for the quarter, beating the consensus estimate of -$2.04 by $0.14.
Is PureTech Health overvalued?
According to Wall Street analysts PureTech Health’s price is currently Undervalued.
Does PureTech Health pay dividends?
PureTech Health does not currently pay dividends.
What is PureTech Health’s EPS estimate?
PureTech Health’s EPS estimate is -1.94.
How many shares outstanding does PureTech Health have?
PureTech Health has 24,168,404 shares outstanding.
What happened to PureTech Health’s price movement after its last earnings report?
PureTech Health reported an EPS of -$1.9 in its last earnings report, beating expectations of -$2.04. Following the earnings report the stock price went down -3.665%.
Which hedge fund is a major shareholder of PureTech Health?
Currently, no hedge funds are holding shares in PRTC
PureTech Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$46.00 (156.41% Upside)
$46.00 (156.41% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.86%
12-Months-Change
Fundamentals
Return on Equity
14.55%
Trailing 12-Months
Asset Growth
-4.61%
Trailing 12-Months
Company Description
PureTech Health
PureTech Health (PRTC) is a biopharmaceutical company focused on discovering, developing, and commercializing highly differentiated medicines for devastating diseases. The company operates in the healthcare and biotechnology sectors, primarily targeting areas such as immunology, inflammation, and central nervous system disorders. PureTech Health is known for its unique approach, which involves leveraging insights from diverse scientific disciplines to address significant healthcare needs.
PRTC Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted PureTech's strong cash position and operational efficiency, progress in core founded entities, and strategic financing with promising valuation for Seaport Therapeutics. However, there are challenges with the need for ongoing external financing for core entities and leadership transitions. The overall sentiment is balanced with strong positive aspects but also significant challenges.View all PRTC earnings summariesPRTC Stock 12 Month Forecast
Average Price Target
$46.00
▲(156.41% Upside)
Technical Analysis
Astria Therapeutics
―
Autolus Therapeutics
―
ADC Therapeutics
―
4D Molecular Therapeutics
―
AbSci
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
1.36% Other Institutional Investors
98.63% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---